The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time

Livers Pub Date : 2023-07-04 DOI:10.3390/livers3030024
Nicholas Noverati, V. Yan, Jay W. Jun, D. Halegoua-DeMarzio, H. Hann
{"title":"The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time","authors":"Nicholas Noverati, V. Yan, Jay W. Jun, D. Halegoua-DeMarzio, H. Hann","doi":"10.3390/livers3030024","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Livers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/livers3030024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.
长期博弈:核苷类似物和时间结构的功能性治疗是可能的
慢性乙型肝炎仍然在全球流行。许多患者使用核苷类似物治疗多年,以防止病毒主动复制。然而,尽管它通常需要连续治疗10年以上,但患者可以从这种病毒中获得功能性治愈。该病例系列介绍了在观察到乙型肝炎表面抗原和病毒载量损失之前,接受不同核苷(t)治疗平均15.3年的患者的功能治疗细节。必须理解,一旦实现功能性治愈,缩短治疗可能是治疗患者的一种可能性,以限制其他终身治疗的相关成本和副作用,直到其他治疗药物获得批准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信